Relative Bioavailability and Tolerability of Two Formulations of Bicalutamide 50-mg Tablets: A Randomized-Sequence, Open-Label, Two-Period Crossover Study in Healthy Korean Male Subjects

Clinical Therapeutics

Volumn 32, Issue 14, 2010, Pages 2496-2501

  Lee, SeungHwan ^a   Yoon, Seo Hyun ^a   Cho, Joo Youn ^a   Shin, Sang Goo ^a   Jang, In Jin ^a   Yu, Kyung Sang ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Bicalutamide; Bioequivalence; Healthy subjects; Pharmacokinetic

Indexed keywords

BICALUTAMIDE; CALUTAMI; GENERIC DRUG; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; ASIAN; ASTHENOPIA; BIOEQUIVALENCE; BLOOD SAMPLING; CROSSOVER PROCEDURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG TOLERABILITY; DYSPEPSIA; ECG ABNORMALITY; ECZEMA; HEADACHE; HEMATURIA; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; IRRITATIVE COUGHING; KOREAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PARESTHESIA; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SINGLE DRUG DOSE; SLEEP DISORDER; SOMNOLENCE; SORE THROAT; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; WEAKNESS;

ADMINISTRATION, ORAL; ADULT; ANDROGEN ANTAGONISTS; ANILIDES; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUGS, GENERIC; HUMANS; MALE; MIDDLE AGED; NITRILES; REPUBLIC OF KOREA; TABLETS; TOSYL COMPOUNDS; YOUNG ADULT;

EID: 79951848654     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.01.017     Document Type: Article

References (14)

1. Furr B.J. The development of Casodex (bicalutamide): Preclinical studies. Eur Urol 1996, 29(Suppl 2):83-95. Review.
2. Casodex [package insert] 2009, AstraZeneca UK Ltd, Macclesfield, UK.
3. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 2008, 53:68-80. European Association of Urology.
4. Pfitzenmaier J., Altwein J.E. Hormonal therapy in the elderly prostate cancer patient. Dtsch Arztebl Int 2009, 106:242-247.
5. Wirth M.P., Hakenberg O.W., Froehner M. Adjuvant hormonal treatment-the bicalutamide early prostate cancer program. Front Radiat Ther Oncol 2008, 41:39-48.
6. Mukherjee A., Kirkovsky L., Yao X.T., et al. Enantioselective binding of Casodex to the androgen receptor. Xenobiotica 1996, 26:117-122.
7. McKillop D., Boyle G.W., Cockshott I.D., et al. Metabolism and enantioselective pharmacokinetics of Casodex in man. Xenobiotica 1993, 23:1241-1253.
8. Cockshott I.D., Oliver S.D., Young J.J., et al. The effect of food on the pharmacokinetics of the bicalutamide ('Casodex') enantiomers. Biopharm Drug Dispos 1997, 18:499-507.
9. McKillop D., Simons P.J., Cockshott I.D., et al. Enantioselective metabolism and pharmacokinetics of Casodex in the male rat. Xenobiotica 1995, 25:623-633.
10. Cockshott I.D. Bicalutamide: Clinical pharmacokinetics and metabolism. Clin Pharmacokinet 2004, 43:855-878. Review.
11. Guidance document for bioequivalence study 2008 [in Korean] Korea Food and Drug Administration, Accessed August 30, 2010. http://betest.kfda.go.kr/country/GUIDANCE%20FOR%20INDUSTRY%20(KFDA_2005).pdf.
12. Ethical principles for medical research involving human subjects World Medical Association Declaration of Helsinki, Accessed August 30, 2010. http://www.wma.net/en/30publications/10policies/b3/index.html.
13. Korea good clinical practice (KGCP) guidelines [in Korean] Korea Food and Drug Administration, Accessed August 30, 2010. http://clinicaltrials.kfda.go.kr/guide/laws/board_list.jsp?category_seq=12.
14. Lee S., Chung Y.J., Kim B.H., et al. Comparative pharmacokinetic evaluation of two formulations of bicalutamide 50-mg tablets: An open-label, randomized-sequence, single-dose, two-period crossover study in healthy Korean male volunteers. Clin Ther 2009, 31:3000-3008.